Issues formal notice to health facilities ordering withdrawal of medicines
The sudden alert about suspected quality issues in tuberculosis medicines supplied by Ayesha Biotech Pvt. Ltd. has sent ripples through health systems and affected communities reliant on these critical drugs. On 19 November 2025, the Central Medical Stores (CMS) issued a formal notice to health facilities, hospital superintendents, council authorities, and chief medical officers, ordering the immediate withdrawal and quarantine of three specific TB medicines from the manufacturer Ayesha Biotech. The products affected include batches of isoniazid 100 mg dispersible tablets and fixed-dose combination tablets containing rifampicin, isoniazid, pyrazinamide, and ethambutol, with expiration dates extending into 2027. These medicines are among the backbone therapies in fighting TB, a disease that remains one of the deadliest infectious killers worldwide.
This content is locked
Login To Unlock The Content!
